"The completion of the initial build-out of our New Jersey manufacturing facility is an important milestone on the path to our PROVENGE license application for marketing approval, which we plan to submit to the FDA later this year," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are committed to bringing PROVENGE to the market to help the many men with late-stage prostate cancer and believe this achievement brings us one step closer to this goal."
PROVENGE® is under USFDA’s Fast Track Designation and when approved will become the first commercially available active cellular immunotherapy designed to stimulate a man's own immune system to treat advanced hormone-refractory prostate cancer.
Read more at Dendreon Corporation.
.jpg)
Comment Preview